Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously presented): A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) an antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein said antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent and in the absence of cells other than cells of said Hodgkin's Disease cell line; and (b) a pharmaceutically acceptable carrier.

2. (Original): The method of claim 1, wherein the antibody is human, humanized or chimeric.

3. (Original): The method of claim 1, further comprising administering chemotherapy to said subject.

4. (Original): The method of claim 1, wherein the antibody is conjugated to a cytotoxic agent.

5. **(Currently amended)**: The method of claim 1, wherein the antibody is a fusion protein comprising an antigen binding region that immunospecifically binds to CD30 and an amino acid sequence of a second protein that is not an antibody.

6. (Original): The method of claim 4 or 5, further comprising administering chemotherapy to said subject.

7. **(Currently amended)**: The method of claim 1, wherein the cytostatic or cytotoxic effect of the antibody is exhibited upon performing a method comprising:

(a) contacting a culture of the Hodgkin's Disease cell line with the antibody, said culture being of about 5,000 cells in a culture area of about 0.33 cm^2, said contacting being for a period of 72 hours;

(b) exposing the culture to 0.5 μCi of ^{3}H-thymidine during the final 8 hours of said 72 hour ~~72-hour~~ period; and

(c) measuring the incorporation of the ^{3}H-thymidine into cells of the culture,

wherein the antibody has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced ^{3}H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the antibody.

8. **(Currently amended)**: A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject an amount of an antibody, ~~a protein,~~ which antibody ~~protein~~ (a) competes for binding to CD30 with monoclonal antibody AC10 or HeFi-1, and (b) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line in the absence of cells other than cells of said Hodgkin's Disease cell line, which amount is effective for the treatment of Hodgkin's Disease.

9-10. (Canceled)

9 ~~11~~. **(Currently amended)**: A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject an amount of an antibody, ~~a protein,~~ which antibody ~~protein~~ (a) comprises the ~~an~~ amino acid sequence that has at least 95% identity to SEQ ID NO:2, (b) immunospecifically binds CD30, and (c) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line in the absence of cells other than cells of said Hodgkin's Disease cell line, which amount is effective for the treatment of Hodgkin's Disease.

10 ~~12~~. (Canceled)

AMY 8-31-06 10 ~~13~~. **(Currently amended)**: The method of any one of claims 8 or 9 ~~11~~, wherein the antibody ~~protein~~ is a human, humanized or chimeric antibody.

11 ~~12 14~~. (Previously presented): The method of any one of claims 8 or 9 ~~11~~, further comprising administering chemotherapy to said subject.

10 ~~13 15~~. **(Currently amended)**: The method of any one of claims 8 or 9 ~~11~~, wherein the antibody ~~protein~~ is conjugated to a cytotoxic agent.

13 ~~14 16~~. **(Currently amended)**: The method of any one of claims 8 or 9 ~~11~~, wherein the antibody ~~protein~~ is fusion protein comprising an antigen binding region that immunospecifically binds to CD30 and the amino acid sequence of a second protein.

14 ~~15 17~~. (Original): The method of claim 13 ~~18~~, further comprising administering chemotherapy to the subject.

15 ~~16.~~ (Previously presented): The method of claim ~~16~~ 14, further comprising administering chemotherapy to the subject.

16 ~~17.~~ **(Currently amended)**: The method of any one of claims 8 or ~~11~~ 9, wherein the cytostatic or cytotoxic effect is exhibited upon performing a method comprising:

(a) contacting a culture of the Hodgkin's Disease cell line with the antibody, ~~protein,~~ said culture being of about 5,000 cells in a culture area of about 0.33 cm^2, said contacting being for a period of 72 hours;

(b) exposing the culture to 0.5 μCi of ^{3}H-thymidine during the final 8 hours of said 72 hour ~~72-hour~~ period; and

(c) measuring the incorporation of the ^{3}H-thymidine into cells of the culture, wherein the antibody ~~protein~~ has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced ^{3}H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the antibody. ~~protein.~~

17 20-66. (Canceled)

18 ~~67.~~ **(Currently amended)** A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) an antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein the antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent and (b) a pharmaceutically acceptable carrier,

wherein the cytostatic or cytotoxic effect of the antibody is exhibited upon performing a method comprising:

(A) immobilizing said antibody in a well, said well having a culture area of about 0.33 cm^2;

(B) adding about 5,000 cells of the Hodgkin's Disease cell line in the presence of RPMI with 20% fetal bovine serum to the well:

(C) culturing the cells in the presence of said antibody and RPMI with 20% fetal bovine serum for a period of 72 hours to form a Hodgkin's Disease cell culture;

(D) exposing the Hodgkin's Disease cell culture to 0.5 μCi/well of ^{3}H-thymidine during the final 8 hours of said 72 hour ~~72-hour~~ period; and

(E) measuring the incorporation of the ^{3}H-thymidine into cells of the Hodgkin's Disease cell culture,

wherein the antibody has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the Hodgkin's Disease cell culture have reduced ^{3}H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the antibody.

18

~~1468.~~ (New): A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) a chimeric, humanized or human antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein the chimeric, humanized or human antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent and (b) a pharmaceutically acceptable carrier,

wherein the cytostatic or cytotoxic effect of the chimeric, humanized or human antibody is exhibited upon performing a method comprising:

(A) contacting a culture of the Hodgkin's Disease cell line with the chimeric, humanized or human antibody, said culture being of about 5,000 cells in a culture area of about 0.33 cm^{2}, said contacting being for a period of 72 hours;

(B) adding a cross-linking antibody to the Hodgkin's Disease cell line, the cross-linking antibody binding to the chimeric, humanized or human antibody;

(C) exposing the culture to 0.5 μCi of ^{3}H-thymidine during the final 8 hours of said 72-hour period; and

(D) measuring the incorporation of the ^{3}H-thymidine into cells of the culture,

wherein the chimeric, humanized or human antibody has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced

^{3}H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the chimeric, humanized or human antibody.